Ipamorelin

Overview

What is Ipamorelin?

Ipamorelin (development code NNC 26-0161) is a pentapeptide identified in 1998 as the first selective growth hormone secretagogue, a compound that stimulates GH release without significantly affecting cortisol, ACTH, or prolactin levels, unlike earlier GHRP-class compounds. It acts as a selective agonist of the ghrelin/GHS receptor. Human pharmacokinetic studies have characterized its absorption and clearance profile, and it has been studied in a controlled clinical trial for postoperative bowel function.

• GH Support
• Recovery
• Sleep Quality
• Body Composition

What the research reports

Circadian GH release context

Outcomes described across the published Ipamorelin literature and ongoing study. Read each as research context rather than a promised personal result.

1. 01

   Selective clean GH release

   Stimulates growth hormone through the ghrelin receptor with minimal effect on cortisol and prolactin, unlike older peptides in the same secretagogue class.

2. 02

   Favourable tolerability data

   Human studies reported good tolerability, including a phase 2 trial where the peptide was well tolerated across a seven day dosing period. Reported in research settings.

3. 03

   Predictable pharmacokinetics

   A 1999 study in 40 volunteers reported dose proportional kinetics, potent growth hormone stimulation and a half-life of about two hours. Reported in research settings.

4. 04

   Recovery research interest

   Used in recovery protocols on the basis of the growth hormone axis, though no published human trial has measured recovery outcomes. Reported in research settings.

5. 05

   Sleep and body composition

   Natural growth hormone release follows a pulsatile, largely nighttime pattern in humans. This has generated research interest in secretagogues like Ipamorelin, though no controlled human trial has measured outcomes tied to timing specifically.

Clinical evidence

Clinical evidence for Ipamorelin

The published record for Ipamorelin, labeled by strength so you can see what is settled and what is emerging.

Interactions

How Ipamorelin pairs with other peptides

CJC-1295 blend

Synergistic for GH release. A GHRH analogue plus a ghrelin mimetic amplifies the pulse through two pathways.

BPC-157 peptide

No known negative interaction reported. The two act on separate primary targets and mechanisms.

MK-677 oral

Stacking growth hormone secretagogues is studied as increasing IGF-1 and insulin resistance risk in the research literature. No published data establishes a safe combined dosing approach, consult the primary literature or a qualified professional before combining research compounds.

Sermorelin

Both raise growth hormone. Combining two secretagogues increases the risk of excessive IGF-1 levels.